Adlai Nortye (ANL) Stock Price, News & Analysis

Company Overview

Adlai Nortye (NASDAQ: ANL) is a China-based company specializing in the research, development, production and commercial distribution of natural nutritional ingredients and health solutions. The company’s core portfolio encompasses a range of bioactive compounds derived from algae, plants and microbial fermentation, aimed at applications in dietary supplements, functional foods, pharmaceuticals and animal nutrition. Since its inception, Adlai Nortye has focused on advancing extraction and purification technologies to deliver high-purity products that meet global quality and safety standards.

The product lineup offered by Adlai Nortye includes a variety of carotenoids such as lutein, zeaxanthin and astaxanthin, as well as specialty algal oils rich in omega-3 fatty acids (DHA and EPA). In addition, the company produces botanical extracts—such as lycopene, anthocyanins and OPCs (oligomeric proanthocyanidins)—and other functional ingredients used in immune support, eye health, cardiovascular wellness and sports nutrition. Supporting its offerings is a contract development and manufacturing organization (CDMO) service that caters to clients seeking custom formulation and scalable production solutions.

Founded in the early 2000s and headquartered in Guangzhou, Adlai Nortye operates multiple manufacturing bases and R&D centers across China, with additional facilities in South America to ensure a stable supply of raw materials. Its global customer base spans North America, Europe, the Asia-Pacific region and Latin America, reflecting the company’s commitment to international regulatory compliance and market-driven innovation. Through collaborations with universities and industry partners, Adlai Nortye continues to expand its pipeline of novel ingredients and to optimize bioprocessing techniques.

Led by a seasoned management team with expertise in nutrition science, industrial bioprocessing and regulatory affairs, Adlai Nortye places strong emphasis on quality control, sustainability and customer partnership. The company’s strategic priorities include investing in advanced fermentation and extraction platforms, enhancing traceability across its supply chain, and accelerating new product introductions that address emerging health and wellness trends worldwide.

Key Stats

• Today's Range: $1.51 to $1.58
• 50-Day Range: $1.40 to $2.05
• 52-Week Range: $1.10 to $4.10
• Volume: 983 shs
• Average Volume: 12,177 shs
• Market Capitalization: $58.30 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Hold

Adlai Nortye Stock Analysis - MarketRank™

Adlai Nortye scored higher than 37% of companies evaluated by MarketBeat, and ranked 694th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Adlai Nortye has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Adlai Nortye has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Adlai Nortye are expected to decrease in the coming year, from ($0.88) to ($0.92) per share.

Price to Book Value per Share Ratio

Adlai Nortye has a P/B Ratio of 2.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of Adlai Nortye has been sold short.

Short Interest Ratio / Days to Cover

Adlai Nortye has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Adlai Nortye has recently decreased by 36.11%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Adlai Nortye does not currently pay a dividend.

Dividend Growth

Adlai Nortye does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.01% of the float of Adlai Nortye has been sold short.

Short Interest Ratio / Days to Cover

Adlai Nortye has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Adlai Nortye has recently decreased by 36.11%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Adlai Nortye insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 35.21% of the stock of Adlai Nortye is held by institutions.

ANL Stock Analysis - Frequently Asked Questions

How have ANL shares performed this year?

Adlai Nortye's stock was trading at $2.69 at the start of the year. Since then, ANL shares have decreased by 41.3% and is now trading at $1.58.

When did Adlai Nortye IPO?

Adlai Nortye (ANL) raised $58 million in an initial public offering (IPO) on Friday, September 29th 2023. The company issued 2,500,000 shares at a price of $23.00 per share.

How do I buy shares of Adlai Nortye?

Shares of ANL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Adlai Nortye own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Adlai Nortye investors own include PayPal (PYPL), Avino Silver & Gold Mines (ASM), nCino (NCNO), Construction Partners (ROAD), Taiwan Semiconductor Manufacturing (TSM), XPeng (XPEV) and Cogent Communications (CCOI).

Company Calendar

• Today: 7/08/2025
• Next Earnings (Estimated): 8/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ANL
• Previous Symbol: NASDAQ:ANL
• CIK: 1944552
• Web: www.adlainortye.com
• Phone: 848-230-7430
• Fax: N/A
• Employees: 127
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Adlai Nortye: $9.00
• High Price Target: $9.00
• Low Price Target: $9.00
• Potential Upside/Downside: +469.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 1.41
• Quick Ratio: 1.41

Sales & Book Value

• Annual Sales: $5 million
• Price / Sales: 11.66
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.69 per share
• Price / Book: 2.29

Miscellaneous

• Outstanding Shares: 36,900,000
• Free Float: N/A
• Market Cap: $58.30 million
• Optionable: Not Optionable
• Beta: -0.95